RxDoctor Payments DataLook up a doctor →

Demondes Haynes, MD

Pulmonary Disease · Jackson, MSNPI 1699716837

Payments from drug & device makers

$808,736in general payments, 2019–2025

Across 1,077 payments — averaging $750.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$794K
  • Actelion Pharmaceuticals US, Inc.$7K
  • Astrazeneca AB$2K
  • Amgen$2K
  • GSK$991
  • AbbVie$488
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$103,80713%
  • Speaking & faculty fees$596,99574%
  • Travel & lodging$86,66711%
  • Food & beverage$21,2563%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808,736 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$39,101
Medicare patients
115
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag27$589,046
OpsumitMacitentan43$523,116
OfevNintedanib Esylate13$162,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$35,848
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$23,158
EliquisApixaban16$13,770
SymbicortBudesonide/Formoterol Fumarate33$11,479
Bevespi AerosphereGlycopyrrolate/Formoterol Fum20$9,895
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,423
Albuterol Sulfate HfaAlbuterol Sulfate121$3,915
Ventolin HfaAlbuterol Sulfate24$1,970
Tadalafil22$1,088
Sildenafil Citrate13$261
Fluticasone Propionate46$254
Prednisone24$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$6,632$1,112,16270 claims
Boehringer IngelheimOfev$122$162,94513 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$794,399$44,53177 claims
GSKTrelegy Ellipta, Anoro Ellipta$991$40,27146 claims
PfizerEliquis$451$13,77016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →